Online inquiry

IVTScrip™ mRNA-Anti-RHD, LFB-R593(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ10225MR)

This product GTTS-WQ10225MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & 5-Methoxy-UTP. It ecodes the monoclonal antibody that targets RHD gene. The antibody can be applied in prevention of feto-maternal allo-immunization in RhD- women research.
Specifications
Product type mRNA
Modified bases 5-Methoxy-UTP
5' Cap Cap 0
Species Homo sapiens
RefSeq NM_001127691.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 6007
UniProt ID Q02161
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-RHD, LFB-R593(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) (GTTS-WQ10225MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ12839MR IVTScrip™ mRNA-Anti-FZD10, ONC-005(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA ONC-005
GTTS-WQ11602MR IVTScrip™ mRNA-Anti-ERBB2, MGAH-22(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA MGAH-22
GTTS-WQ15038MR IVTScrip™ mRNA-Anti-CD47, SRF-231(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA SRF-231
GTTS-WQ5203MR IVTScrip™ mRNA-Anti-CD22, CAT-8015(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA CAT-8015
GTTS-WQ9887MR IVTScrip™ mRNA-Anti-pcrV, KB001-A(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA KB001-A
GTTS-WQ6302MR IVTScrip™ mRNA-Anti-TNFRSF10B, CS-1008(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA CS-1008
GTTS-WQ4144MR IVTScrip™ mRNA-Anti-PDCD1, BI-754091(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA BI-754091
GTTS-WQ545MR IVTScrip™ mRNA-Anti-ERBB2, 4D5-8(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA 4D5-8
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW